We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PSX:NYSEPhillips 66 Analysis

Data as of 2026-05-25 - not real-time

$177.69

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Phillips 66 is trading at $177.69, comfortably above its 20‑day ($174.60) and 50‑day ($172.19) moving averages and well above the 200‑day SMA ($146.88), confirming a strong bullish bias. The MACD line sits at 2.57 above its signal (2.30) and the RSI is at a neutral 55, indicating room for further upside without immediate overbought pressure. Technicals are reinforced by a support level near $163.13 and a resistance ceiling around $184.72, suggesting a near‑term upside potential of roughly 5.5% as reflected in the computed upside/downside metric. Fundamentals show a PE of 17.5 versus an industry average of 21.6, positioning the stock as relatively cheap on a value basis, while the dividend yield of 2.86% and a payout ratio under 50% support a sustainable income stream. Recent earnings have outperformed expectations, with analysts upgrading sentiment and highlighting a $8 billion debt‑paydown plan through 2027, which should improve balance‑sheet resilience. However, the company carries a high debt‑to‑equity of 91, a negative free‑cash‑flow figure and operates in the volatile energy sector, exposing it to regulatory and transition risks. Volatility remains elevated at 35% over the past 30 days, though beta is low, indicating limited correlation with broader market moves. The consensus recommendation is a “Buy” with a median target of $190, reinforcing the upside thesis. Overall, Phillips 66 blends modest growth prospects from a refining up‑cycle with solid dividend appeal, but investors should monitor debt reduction progress and macro‑energy dynamics.
In the short term, the confluence of bullish technicals, earnings beat, and a modest upside ceiling makes a buying opportunity attractive. Over the medium horizon, the company’s strategic focus on debt reduction, renewable fuels, and a resilient dividend supports a continued positive stance, while long‑term considerations must weigh sector transition risks and the high leverage profile.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 9/10

Key Factors

  • Price above 20‑day and 50‑day SMAs with bullish MACD
  • Earnings beat and upgraded analyst sentiment
  • Visible upside to resistance (~5.5%) and attractive dividend yield

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Debt‑paydown plan targeting $8 B reduction by 2027
  • Refining up‑cycle and solid segment profitability
  • Sustainable dividend supported by earnings and cash flow

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and negative free cash flow
  • Energy transition and regulatory exposure
  • Diversification into renewable fuels and midstream assets

Key Metrics & Analysis

Financial Health

Revenue Growth6.90%
Profit Margin3.07%
P/E Ratio17.5
ROE14.55%
ROA3.80%
Debt/Equity91.39
P/B Ratio2.5
Op. Cash Flow$2.5B
Free Cash Flow$-1134499968
Industry P/E21.6

Technical Analysis

TrendBullish
RSI55.3
Support$163.13
Resistance$184.72
MA 20$174.60
MA 50$172.19
MA 200$146.88
MACDBullish
VolumeStable
Fear & Greed Index91.61

Valuation

Fair Value$21.74
Target Price$187.42
Upside/Downside5.48%
GradeUndervalued
TypeBlend
Dividend Yield2.86%

Risk Assessment

Beta0.02
Volatility35.19%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.